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Gout is the most common inflammatory arthritis. 
Worldwide, gout and hyperuricaemia are on the rise 
owing mainly to dietary changes, obesity, the metabolic 
syndrome and increasing age. In the past 2 decades the 
prevalence of gout has doubled owing mostly to changes 
in diet. Western diets rich in meat, seafood, fructose-sweetened 
drinks and beer have especially been identified.[1] 
Gout has two clinical presentations that affect the musculoskeletal 
system – acute arthritis and chronic tophaceous gout. The acute 
attack results in the person experiencing severe pain and swelling of 
the affected joint, which impairs quality of life. In between attacks 
patients are asymptomatic.
In tophaceous gout, patients develop a chronic debilitating arthritis 
with loss of function. Tophi cause erosions of joints, but also deposit 
in the skin and soft tissue, including the bursae, tendons and 
articular cartilage. Tophi are the pathognomonic features of gout. 
Renal manifestations include kidney stones and rarely an interstitial 
nephritis. 
The acute attack can be very easily managed by using non-steroidal 
anti-inflammatory drugs (NSAIDs), colchicine or glucocortico-
steroids, followed up by lifestyle modification and, if appropriate, 
urate-lowering therapy (ULT). The indications to commence ULT 
are:
• Recurrent attacks (≥2).
• Tophaceous gout.
• Radiological evidence of erosive disease.
Pathogenesis
Gout results from the accumulation of uric acid, which is formed 
as the end result of purine metabolism. Xanthine oxidase is an 
import enzyme in the purine pathway, which ultimately results 
in the formation of uric acid. The majority of purines are 
endogenous, while diet is a source of exogenous purines. High 
fructose results in hyperuricaemia via the fructose phosphokinase 
shunt.
The body regulates uric acid primarily in the kidneys. After uric 
acid is filtered by the glomerulus, almost all of it is reabsorbed in the 
proximal convoluted tubule. This is followed by secretion of uric acid 
back into the tubules before being reabsorbed again. The net effect 
is that only 5 - 10% of filtered uric acid is lost through the kidneys. 
There are various transporters within the tubules that are involved in 
this complex uric acid transport. Uric acid transporter 1 (URAT1) 
and organic anion transporter 4 (OAT4) are transporters in the 
proximal tubules that reabsorb uric acid and have been identified as 
targets for future treatments.
When the serum concentration of uric acid rises above the 
saturation point to >0.42  mmol/L, uric acid crystallises. These 
are deposited into joints and various tissues, forming tophi. The 
microtophi are sealed off by proteins, and consequently do not cause 
an inflammatory response. The tophi may rupture, exposing the 
monosodium urate (MSU) crystals to circulating macrophages. Joint 
damage, dehydration and cool peripheral temperatures may cause the 
microtophi to rupture, thus exposing the MSU to tissue macrophages. 
MSU crystals are then engulfed by macrophages, which set off 
an inflammatory response where interleukin 1 beta, among other 
pro-inflammatory cytokines, is activated. This results in an acute 
inflammatory process with swelling, redness, warmth and tenderness 
of the affected joint.[2]
Diagnosis
The definitive diagnosis of gout is made when MSU crystals are 
observed in a joint aspirate. Any patient who presents with an acute 
monoarthritis needs the joint aspirated to exclude sepsis and has to 
be assessed for crystals. A history of recurrent self-limiting joint pain 
is suggestive of gout. When one includes podagra and the presence 
of tophi, the specificity increases. Serum urate is often helpful with 
the diagnosis, but it cannot be the only criterion on which the 
diagnosis is based. The urate level may be normal in an acute attack 
and conversely may be elevated in asymptomatic individuals.[3] The 
demonstration of MSU does not exclude the possibility of another 
cause of monoarthritis. Importantly, sepsis and trauma may coexist 
in an inflamed joint.
Once a diagnosis of gout is made, the modifiable risk factors must 
be assessed.
The American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) 2015 gout classification criteria (Table 1) 
have recently been published. They propose a 3-step process for making 
the diagnosis of gout:[4]
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• Step 1. Entry criterion: at least 1 episode of swelling or tenderness 
in a peripheral joint or bursa.
• Step 2. Sufficient clinical criteria (if met, can classify as gout; then 
step 3 is not necessary): presence of MSU crystals in a symptomatic 
joint or bursa or the presence of tophus.
• Step 3. If Step 2 does not confirm the diagnosis, then use the 
given scoring system in Table 1. A score of ≥8 is sufficient for the 
diagnosis of gout. 
Treatment
The acute attack
The management of the acute attack is very effective and may 
be a contributing factor as to why gout is poorly managed. The 
effectiveness of the acute management may make the patient forget 
about the more important ULT. 
NSAIDs, colchicine and corticosteroids are all effective in 
managing the acute attack. The choice of anti-inflammatory drug 
will depend on the risk of side-effects and comorbidities. Patients do 
report that early treatment at the first sign of pain may abort a full 
attack. Once established, the acute attack will last for several days 
before it resolves. 
Colchicine is particularly effective in the acute attack, but the 
therapeutic window is very narrow. Gastrointestinal side-effects 
are especially common and may cause unwanted problems in 
patients who are immobilised as a result of the acute attack. Oral 
corticosteroids are equally effective; however, patient selection is 
important, e.g. corticosteroids are more effective than NSAIDs in 
patients with renal disease but not ideal in diabetics with sepsis. The 
patient profile will determine the agent of choice.[5-7]
Intra-articular steroids are also effective in the acute attack, but 
have not been well studied. They are favoured in acute monoarthritis 
after aspirating the joint to dryness.
Lifestyle modification
Lifestyle modification and dietary changes should be addressed 
at the first attack of gout. One should screen for comorbidities 
because of the strong association with the metabolic syndrome. 
Hypertension, diabetes and dyslipidaemia should be considered. 
Chronic medication should be reviewed to ensure that there are 
no drugs that will cause hyperuricaemia. Alternatives to thiazide 
diuretics should be selected and low-dose aspirin indications 
scrutinised. Weight reduction should be advised and alcohol 
intake reduced. Beer must be avoided at all costs. Foods high in 
purines should be avoided. Most people are aware that offal and 
oily fish are sources of purines, but certain vegetables are also high 
in purines. Mushrooms, broccoli and spinach have a moderate 
content of purines and may also need to be avoided. High-fructose 
corn syrup (HFCS) is an artificial sweetener that is used in many 
different food products. A high fructose intake will increase uric 
acid production via the phosphokinase shunt. The ingredients of 
fruit juices, cereals, sauces, syrups and even breads may include 
HFCS. 
Angiotensin receptor blockers have a mild uricosuric effect and 
may help with lowering uric acid levels.
Urate-lowering therapy
The goal of ULT is to decrease the uric acid level below the saturation 
point. A treat-to-target strategy should be started with the goal of 
lowering the urate level to 0.35 mmol/L. In tophaceous gout the target 
should be lower. 
Allopurinol is the first line of treatment for gout. It is a xanthine 
oxidase inhibitor and decreases uric acid production. It has been 
shown to be effective in both under-excretors (under-secretors) and 
over-producers of uric acid. Ideally, allopurinol should be started 
once the acute attack has settled. Twenty percent of patients will 
experience the acute attack when starting allopurinol. Colchicine 
should be used as prophylaxis to prevent acute flares when starting 
daily allopurinol – up to at least 3 months.
Allopurinol should be started at 100  mg daily and the uric acid 
levels checked every 4 weeks. Allopurinol should be increased by 
100  mg until the target is reached. Allopurinol hypersensitivity 
syndrome (AHS) is a rare side-effect in 0.1% of patients. It entails 
a desquamating rash, fever and hepatitis and is potentially life 
threatening. Pre-existing renal disease is the main risk factor for 
AHS. Patients should be advised to discontinue allopurinol if they 
develop a rash and seek urgent medical attention.[6-8]
Febuxostat is another xanthine oxidase inhibitor that is used to 
lower uric acid.
Probenecid is a uricosuric agent and an alternative to allopurinol. 
It inhibits urate reabsorption in the proximal convoluted tubule. 
Table 1. The ACR/EULAR 2015 gout classification criteria
Pattern of joint involvement Ankle or mid-foot (1) Podagra (2)
Characteristics
• Erythema overlying the joint
• Cannot bear touch or pressure
• Difficulty walking/using the joint
One characteristic (1) Two characteristics (2) Three characteristics (3)
Time course of typical episode (≥2)
• Maximal pain within 24 hours
• Resolution of symptoms within 14 days
• Complete resolution between attacks
One typical episode (1) Recurrent typical episodes (2)
Clinical evidence of a tophus Present (4)
Serum uric acid level <0.24 mmol/L (−4) 0.36 - 0.48 mmol/L (2)
0.48 - 0.60 mmol/L (3)
>0.6 mmol/L (4)
Synovial fluid analysis MSU negative (−2)
Imaging
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It is contraindicated in renal failure and in patients who have 
urolithiasis. Probenecid is not as effective as allopurinol.
Losartan and fenofibrate both have mild uricosuric effects and may 
be used in combination with the conventional therapies to lower uric 
acid levels.
Pegloticase is a pegylated recombinant uricase that converts uric 
acid to allopurinol. It has been licensed by the US Food and Drug 
Administration (FDA) for refractory tophaceous gout. It is associated 
with transfusion reactions and immunogenicity.
Asymptomatic hyperuricaemia
Hyperuricaemia has been shown to be associated with the metabolic 
syndrome. However, only a third of patients with hyperuricaemia 
develop gout. It is still not clear whether hyperuricaemia is an 
independent risk factor for cardiovascular disease and whether 
initiating therapy in patients with asymptomatic hyperuricaemia will 
be beneficial. Currently, ULT is not indicated in these patients. This 
is an area of ongoing research.[7]
Conclusion 
Gout and hyperuricaemia are becoming more common. Gout can 
be effectively managed by targeting serum acid and aggressively 
lowering the level to 0.35 mmol/L. Comorbid diseases and other 
drugs provide challenges in managing gout. Lifestyle modification 
is an essential component in the management of gout, particularly 
dietary changes, maintaining a normal weight and a reduction/
avoidance of alcohol. The management of asymptomatic hyper-
uricaemia and its role in cardiovascular disease are areas of ongoing 
research.
References
1. Hak AE, Choi HK. Lifestyle and gout. Curr Opin Rheumatol 2008;20:178-186. [http://dx.doi.
org/10.1097/BOR.0b013e3282f524a2]
2. Terkeltaub R. Update on gout: New therapeutic strategies and options. Nat Rev Rheumatol 2010;6:30-
38. [http://dx.doi.org/10.1038/nrrheum.2009.236]
3. Malik A, Schumacher HR, Dinnella JE. Clinical diagnostic criteria for gout: Comparison with the 
gold standard of synovial fluid crystals. J Clin Rheumatol 2009;15:22-24. [http://dx.doi.org/10.1097/
RHU.0b013e3181945b79]
4. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout Classification Criteria. Arthritis Rheumatol 
2015;67(10):2557-2568. [http://dx.doi.org/10.1002/art.39254]
5. Baker JF, Schumaker H. Update of gout and hyperuricaemia. Int J Clin Pract 2010;64(3):371-377. 
[http://dx.doi.org/10.1111/j.1742-1241.2009.02188.x]
6. Neogi T. Clinical practice of gout. N Engl J Med 2011;364:443-452. [http://dx.doi.org/10.1056/
NEJMcp1001124]
7. Weisman M. Targeted Treatment of the Rheumatic Diseases. Philadelphia: Saunders Elsevier, 
2010:293-302.
8. Khanna D, Fitzgerald J, Khanna P, et al. 2012 American College of Rheumatology guidelines 
for the management of gout. Part 1: Systematic non-pharmacological and pharmacologic 
therapeutic approaches to hyperuricaemia. Arthritis Care Research 2012;64(10):1431-1446. 
[http://dx.doi.org/10.1002/acr] 
